Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Enzalutamide is an androgen receptor inhibitor. It works by blocking the action of testosterone. It is used for the treatment of metastatic castration resistant prostate cancer. Some studies suggest that enzalutamide also inhibits breast cancer cell growth.
Enzalutamide is developed to prevent the androgen growth of castrate-resistant prostate cancers. This drug works by keeping androgens from binding to the androgen receptors on prostate cancer cells.
Related Journals of Enzalutamide
Journal of Prostate Cancer, Journal of Cancer Science & Therapy.